GH Research (GHRS) Income from Continuing Operations (2020 - 2025)
GH Research (GHRS) recorded quarterly Income from Continuing Operations of 14137000.0 in Q4 2025, down 0.83% quarter-over-quarter from 14020000.0 in Q3 2025, and down 60.61% on a YoY basis from 35890935.68 in Q4 2024.
GH Research (GHRS) Income from Continuing Operations (2020 - 2025) Analysis & Trends
GH Research's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 14137000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 60.61% year-over-year to 14137000.0; the TTM figure through Dec 2025 stood at 48258000.0 (down 23.86% YoY), while the FY2025 annual figure was 48258000.0, down 23.86% from the prior year.
- Income from Continuing Operations was 14137000.0 for Q4 2025 at GH Research, down from 14020000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 334000.0 in Q2 2022 to a low of 16586000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 7723200.0 across 5 years, with a median of 8265500.0 in 2023.
- The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations tumbled 2961.67% in 2021, then soared 115.72% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 4091000.0 in 2021, then tumbled by 305.43% to 16586000.0 in 2022, then surged by 32.04% to 11272000.0 in 2023, then climbed by 21.91% to 8802000.0 in 2024, then sank by 60.61% to 14137000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 14137000.0 (Q4 2025), 14020000.0 (Q3 2025), and 9289000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | -14.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.14 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -9.29 Mn |
| Mar 31, 2025 | -10.81 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Sep 30, 2024 | -12.11 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -7.67 Mn |
| Dec 31, 2023 | -11.27 Mn |
| Sep 30, 2023 | -5.65 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -10.94 Mn |
| Dec 31, 2022 | -16.59 Mn |
| Sep 30, 2022 | -441,000.00 |
| Jun 30, 2022 | 334,000.00 |
| Mar 31, 2022 | -5.76 Mn |
| Dec 31, 2021 | -4.09 Mn |
| Sep 30, 2021 | -1.84 Mn |
| Jun 30, 2021 | -2.13 Mn |
| Mar 31, 2021 | -1.15 Mn |